Andrea Napolitano

Royal Marsden Hospital — United Kingdom

Medicine · Health Sciences

31h-index4.0kcitations172works5.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Occupational and environmental lung diseases(50), Sarcoma Diagnosis and Treatment(47), Gastrointestinal Tumor Research and Treatment(31), Vascular Tumors and Angiosarcomas(16), Gastric Cancer Management and Outcomes(14)

Publications172 total

Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With <i>KIT</i> Exon 9 Mutations
JAMA Oncology·2026Open Access
Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment
JAMA Oncology·2025· 4 cited
A novel risk score after neoadjuvant imatinib predicts relapse-free survival in patients with gastrointestinal stromal tumours (GIST)
European Journal of Surgical Oncology·2025
2756eTiP A prospective international observational study on low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid LGFMS/SEF: A PUSH platform study
Annals of Oncology·2025
Imatinib’s last lessons? A roadmap to cure
Annals of Oncology·2025
Corrigendum to ‘Robotic MRI/CT Guided Multiregional ‘smart’ Biopsy for Characterization of Tumor Heterogeneity: A Prospective Development Study’ [Acad Radiol 32/2 (2025) 1100-1107]
Academic Radiology·2025· 1 citedOpen Access
Efficacy and cardiac safety of aldoxorubicin in metastatic solitary fibrous tumour
Rare Tumors·2025Open Access
UK clinical practice guidelines for the management of patients with constitutional <i>POT1</i> pathogenic variants
Journal of Medical Genetics·2025· 4 citedOpen Access
MDM2 inhibitors in sarcomas: results and next steps
Current Opinion in Oncology·2025· 1 cited
Identifying and managing rare subtypes of gastrointestinal stromal tumors
Expert Review of Gastroenterology & Hepatology·2025· 2 cited
134P Chemotherapy in giant cell tumour of soft tissue: A case-series
ESMO Open·2025Open Access
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Journal for ImmunoTherapy of Cancer·2025· 15 citedOpen Access
Ossifying fibromyxoid tumours: A case series
European Journal of Cancer·2025· 4 citedOpen Access
Novel Therapeutics in Soft Tissue Sarcoma
Cancers·2024· 9 citedOpen Access
Robotic MRI/CT Guided Multiregional ‘smart’ Biopsy for Characterization of Tumor Heterogeneity: A Prospective Development Study
Academic Radiology·2024Open Access
International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms
The American Journal of Surgical Pathology·2024· 4 citedOpen Access
Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group
ESMO Open·2024· 7 citedOpen Access
S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models
Oncogene·2024· 1 citedOpen Access
The observational EURACAN prospective clinical registry dedicated to epithelioid hemangioendothelioma: The protocol of an international and collaborative effort on an ultra-rare entity
PLoS ONE·2024· 3 citedOpen Access
First-Line Tyrosine Kinase Inhibitors in Soft-Tissue Sarcomas: A Role for Anlotinib?
Clinical Cancer Research·2024
page 1 of 9Next →

Frequent Co-authors

Michele Carbone(22), Harvey I. Pass(21), Haining Yang(21), Bruno Vincenzi(21), Daniele Santini(16), Sandra Pastorino(15), Giuseppe Tonini(15), Giovanni Gaudino(13), Mika Tanji(10), Laura Pellegrini(9), Robin L. Jones(9), Francesco Pantano(8), Ian Pagano(7), Giuseppe Badalamenti(7), Angela Bononi(6), David Larson(6), Francine Baumann(6), Erin Flores(6), Amy Powers(6), Mariella Spalato Ceruso(6)